Last Updated: March 26, 2020, 7:30am EDT
It is our pleasure to announce that in honour of the late Mitchell Baran, the founder and leader of the Trudell Medical Group of Companies, the City of London has renamed the portion of Third Street that two of the Trudell Companies are located to “Baransway Drive”.
So why aren’t they used more widely?
A new review suggests that wider use of OPEP devices could reduce exacerbations and reduce hospital visits.
Presented at the British Thoracic Society December 2018.
Having a child with asthma can be stressful for parents, especially for financially strapped ones struggling to pay for an arsenal of puffers and pills for their child’s treatment. Because of this, those healthcare professionals who recommend spacer chambers may suggest one of many lower-cost versions that are available on the market today. But focusing only on cost may be putting a child’s health at risk.
Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the Aerobika* oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1
For people recovering from an acquired or traumatic brain injury, swallowing rehabilitation can be especially challenging because they may experience a period of post-traumatic amnesia. This can limit their ability to form new memories, making it difficult to learn the swallowing exercises that may help them eat again.
May 1, 2018: Today is the 20th annual World Asthma Day, an event held each May to raise awareness of Asthma worldwide. World Asthma Day is organized by the Global Initiative for Asthma, or GINA (www.ginasthma.org), a World Health Organization collaborative and 501(c)3 organization founded in 1993.
Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control.
A recent article in Pulmonary Pharmacology and Physiology1 provides in vitro evidence that the AeroChamber Plus* Flow-Vu* valved holding chamber (or spacer) delivers aerosolized drug more effectively than other chambers, a view further supported in a new literature review published in Therapeutic Advances in Respiratory Disease.2
Trudell Medical UK Ltd (TM-UK) is now the UK distributor for the full AeroChamber Plus* range of Valved Holding Chambers (VHCs)
Starting January 1st, 2018, under the new OHIP+ program, the Ontario Drug Benefit Program will cover AeroChamber Plus* Flow-Vu* chambers for children 12 years of age and under. Children prescribed a Metered Dose Inhaler (MDI) for their asthma will now be eligible for one (1) chamber per year under this new program. A prescription must be provided by a doctor or nurse practitioner in order to be eligible for reimbursement.